PDK1 and hepatocellular carcinoma: In contrast, PDK1 activation can be suppressed by PPARγ-coactivator-1α (PGC-1α), although PPARγ appears to be upregulated in HCC cells and human HCC tissues resistant to Sorafenib [127].